Table 1 Clinicopathological and treatment characteristics of patients

No

121

121

Age,(mean, s.d)

57.21(10.63)

55.73(10.45)

0.276

Range

28–75

20–72

< 60

72(59.50%)

81(66.90%)

0.230

≥ 60

49(40.50%)

40(33.10%)

KPS

70

0

0

0.511

80

3(2.50%)

5(4.10%)

90

48(39.70%)

54(44.60%)

100

70(57.90%)

62(51.20%)

FIGO stage

IB3-II

74(61.20%)

68(56.20%)

0.433

III-IVA

47(38.80%)

53(43.80%)

in detail

IB3

38(31.40%)

26(21.50%)

0.210

IIA2

15(12.40%)

10(8.30%)

IIB

21(17.40%)

32(26.40%)

IIIA

1(0.80%)

3(2.50%)

IIIB

3(2.50%)

4(3.30%)

IIIC1

26(21.50%)

29(24.00%)

IIIC2

11(9.10%)

15(12.40%)

IVA

6(5.00%)

2(1.70%)

Histologic type

Squamous cell carcinoma

103(85.10%)

105(86.80%)

0.870

Adenocarcinoma

13(10.70%)

13(10.70%)

Adenosquamous carcinoma

5(4.10%)

3(2.50%)

Concurrent chemotherapy cycles received

4

9(7.40%)

7(5.80%)

0.719

5

33(27.30%)

38(31.40%)

6

79(65.30%)

76(62.80%)

Adjuvant chemotherapy cycles received

0

69(57.00%)

63(52.10%)

0.719

2

5(4.10%)

8(6.60%)

3

1(0.80%)

2(1.70%)

4

46(38.00%)

48(39.70%)

EBRT dose

45 Gy/25f

42(34.70%)

45(37.20%)

0.922

50 Gy/25f

53(43.80%)

51(42.10%)

50.4 Gy/28f

26(21.50%)

25(20.70%)

SIB prescribed

50 Gy/25f

14(11.60%)

21(17.40%)

0.441

61.6 Gy/28f

26(21.50%)

24(19.80%)

No

81(66.90%)

76(62.80%)

ICBT dose

30 Gy/5f

76(62.80%)

72(59.50%)

0.598

28 Gy/4f

45(37.20%)

49(40.50%)

Baseline blood count test (mean, s.d)

WBC, *10^9/L

6.39(3.74)

6.32(3.76)

0.887

ANC, *10^9/L

4.60(3.26)

4.43(3.51)

0.704

HGB, g/L

120.60(15.08)

118.10(14.80)

0.194

PLT, *10^9/L

214.03(78.92)

208.98(82.23)

0.626

LYM,*10^9/L

1.37(0.59)

1.41(0.61)

0.663

Baseline HT(excluding lymphopenia)

Grade 0

53(43.80%)

47(38.8%)

0.112

Grade 1

61(50.4%)

54(44.6%)

Grade 2

7(5.8%)

20(16.5%)

Grade 3

0

0

Grade 4

0

0